Editor’s Choice Articles are selected based on suggestions from Cancers’ Academic Editors worldwide. The Editors select a small number of recently published articles that they consider particularly interesting to our readers or important in their respective fields of research. You are welcome to read the Editor’s Choice Articles related to cancer biomarkers, a curated list of high-quality articles from 2022 to 2023 in Cancers (ISSN: 2072-6694). The full list of Editor's Choice Articles can be viewed at the following link: https://www.mdpi.com/journal/cancers/editors_choice.

The list of relevant papers can be seen below:

“Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy”
by Yuta Myojin, Takahiro Kodama, Ryotaro Sakamori, Kazuki Maesaka, Takayuki Matsumae, Yoshiyuki Sawai, Yasuharu Imai, Kazuyoshi Ohkawa, Masanori Miyazaki, Satoshi Tanak et al.
Cancers 2022, 14(4), 883; https://doi.org/10.3390/cancers14040883
Available online: https://www.mdpi.com/2072-6694/14/4/883

“The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma”
by Betul Gok Yavuz, Saumil Datar, Shadi Chamseddine, Yehia I. Mohamed, Michael LaPelusa, Sunyoung S. Lee, Zishuo Ian Hu, Eugene J. Koay, Hop S. Tran Cao, Prasun Kumar Jalal et al.
Cancers 2023, 15(19), 4875; https://doi.org/10.3390/cancers15194875  
Available online: https://www.mdpi.com/2072-6694/15/19/4875

“HPRT1 Promotes Chemoresistance in Oral Squamous Cell Carcinoma via Activating MMP1/PI3K/Akt Signaling Pathway”
by Tong Wu, Zan Jiao, Yixuan Li, Xuan Su, Fan Yao, Jin Peng, Weichao Chen and Ankui Yang
Cancers 2022, 14(4), 855; https://doi.org/10.3390/cancers14040855  
Available online: https://www.mdpi.com/2072-6694/14/4/855

“Comprehensive Approach to Distinguish Patients with Solid Tumors from Healthy Controls by Combining Androgen Receptor Mutation p.H875Y with Cell-Free DNA Methylation and Circulating miRNAs”
by Elena Tomeva, Olivier J. Switzeny, Clemens Heitzinger, Berit Hippe and Alexander G. Haslberger
Cancers 2022, 14(2), 462; https://doi.org/10.3390/cancers14020462  
Available online: https://www.mdpi.com/2072-6694/14/2/462

“Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models”
by Ha-Yeon Shin, Eun-ju Lee, Wookyeom Yang, Hyo Sun Kim, Dawn Chung, Hanbyoul Cho and Jae-Hoon Kim
Cancers 2022, 14(3), 829; https://doi.org/10.3390/cancers14030829  
Available online: https://www.mdpi.com/2072-6694/14/3/829

“Diverse Roles and Targets of miRNA in the Pathogenesis of Testicular Germ Cell Tumour”
by Mrinal K. Das, Øyvind P. Haugen and Trine B. Haugen
Cancers 2022, 14(5), 1190; https://doi.org/10.3390/cancers14051190  
Available online: https://www.mdpi.com/2072-6694/14/5/1190

“Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies”
by Radoslav Janostiak, Ariadna Torres-Sanchez, Francesc Posas and Eulàlia de Nadal
Cancers 2022, 14(5), 1265; https://doi.org/10.3390/cancers14051265  
Available online: https://www.mdpi.com/2072-6694/14/5/1265

“Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy”
by Pauline Gilson, Jean-Louis Merlin and Alexandre Harlé
Cancers 2022, 14(6), 1384; https://doi.org/10.3390/cancers14061384  
Available online: https://www.mdpi.com/2072-6694/14/6/1384

“Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer”
by Camille Domergue, Elodie Martin, Camille Lemarié, Pascal Jézéquel, Jean-Sebastien Frenel, Paule Augereau, Mario Campone and Anne Patsouris
Cancers 2022, 14(10), 2509; https://doi.org/10.3390/cancers14102509  
Available online: https://www.mdpi.com/2072-6694/14/10/2509

“Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer”
by Samuel J. Galgano, Andrew M. McDonald, Janelle T. West and Soroush Rais-Bahrami
Cancers 2022, 14(14), 3302; https://doi.org/10.3390/cancers14143302  
Available online: https://www.mdpi.com/2072-6694/14/14/3302

“Involvement of HHV-4 (Epstein–Barr Virus) and HHV-5 (Cytomegalovirus) in Inflammatory Bowel Disease and Colorectal Cancer: A Meta-Analysis”
by Luigi Marongiu, Sascha Venturelli and Heike Allgayer
Cancers 2022, 14(20), 5085; https://doi.org/10.3390/cancers14205085  
Available online: https://www.mdpi.com/2072-6694/14/20/5085

“Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?”
by Mariana Tannoury, Delphine Garnier, Santos A. Susin and Brigitte Bauvois
Cancers 2022, 14(24), 6026; https://doi.org/10.3390/cancers14246026  
Available online: https://www.mdpi.com/2072-6694/14/24/6026

“Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis”
by Morten Borg, Sara Witting Christensen Wen, Rikke Fredslund Andersen, Signe Timm, Torben Frøstrup Hansen and Ole Hilberg
Cancers 2023, 15(15), 3959; https://doi.org/10.3390/cancers15153959  
Available online: https://www.mdpi.com/2072-6694/15/15/3959

“Serum Insights: Leveraging the Power of miRNA Profiling as an Early Diagnostic Tool for Non-Small Cell Lung Cancer”
by Radoslaw Charkiewicz, Anetta Sulewska, Robert Mroz, Alicja Charkiewicz, Wojciech Naumnik, Marcin Kraska, Attila Gyenesei, Bence Galik, Sini Junttila, Borys Miskiewicz et al.
Cancers 2023, 15(20), 4910; https://doi.org/10.3390/cancers15204910
Available online: https://www.mdpi.com/2072-6694/15/20/4910

“A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)”
by Yvonne L. E. Ang, Xiaotian Zhao, Thanyanan Reungwetwattana, Byoung-Chul Cho, Bin-Chi Liao, Rebecca Yeung, Herbert H. Loong, Dong-Wan Kim, James Chih-Hsin Yang, Sun Min Lim et al.
Cancers 2023, 15(20), 4999; https://doi.org/10.3390/cancers15204999  
Available online: https://www.mdpi.com/2072-6694/15/20/4999

“Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period”
by Thaïs M. L. Tong, Esther Bastiaannet, Frank M. Speetjens, Christian U. Blank, Gregorius P. M. Luyten, Martine J. Jager, Marina Marinkovic, T. H. Khanh Vu, Coen R. N. Rasch, Carien L. Creutzberg et al.
Cancers 2023, 15(22), 5419; https://doi.org/10.3390/cancers15225419  
Available online: https://www.mdpi.com/2072-6694/15/22/5419

“Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma—What Do We Already Know”
by Jacek Baj, Łukasz Bryliński, Filip Woliński, Michał Granat, Katarzyna Kostelecka, Piotr Duda, Jolanta Flieger, Grzegorz Teresiński, Grzegorz Buszewicz, Marzena Furtak-Niczyporuk et al.
Cancers 2022, 14(6), 1493; https://doi.org/10.3390/cancers14061493  
Available online: https://www.mdpi.com/2072-6694/14/6/1493

“Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma”
by Marcus T. T Roalsø., Øyvind H. Hald, Marina Alexeeva and Kjetil Søreide
Cancers 2022, 14(3), 546; https://doi.org/10.3390/cancers14030546  
Available online: https://www.mdpi.com/2072-6694/14/3/546

“Development and Validation of Blood-Based Predictive Biomarkers for Response to PD-1/PD-L1 Checkpoint Inhibitors: Evidence of a Universal Systemic Core of 3D Immunogenetic Profiling across Multiple Oncological Indications”
by Ewan Hunter, Matthew Salter, Ryan Powell, Ann Dring, Tarun Naithani, Maria Eleni Chatziioannou, Abel Gebregzabhar, Mutaz Issa, Jayne Green, Serene Ng et al.
Cancers 2023, 15(10), 2696; https://doi.org/10.3390/cancers15102696  
Available online: https://www.mdpi.com/2072-6694/15/10/2696

You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.

Cancers Editorial Office